Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of Pain

• Publication date

  2013-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jpain.2013.04.011PMID 23816949
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment.

  2013cited by this paper
• Effect of abuse-deterrent formulation of OxyContin.

  2012cited by this paper
• Route of administration for illicit prescription opioids: a comparison of rural and urban drug users

  2010cited by this paper
• Integrating nine prescription opioid analgesics and/or four signal detection systems to summarize statewide prescription drug abuse in the United States in 2007

  2009cited by this paper
• The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS).

  2007cited by this paper
• Motives, diversion and routes of administration associated with nonmedical use of prescription opioids.

  2007cited by this paper
• 2006 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS)

  2007cited by this paper
• Abuse of prescription drugs and the risk of addiction.

  2006cited by this paper
• A Profile of OxyContin Addiction

  2004cited by this paper

• Systematic review of real-world data associated with opioid scheduling and nonmedical use.

  2026cites this paper
• Evaluation of Abuse Deterrent Formulations of Oxycodone Products: Real-World Data from an Enriched Population of Substance Users Assessed with the Addiction Severity Index-Multimedia Version (ASI-MV®)

  2026cites this paper
• Abuse-deterrent formulations and opioid-related harms in North Carolina, 2010-2018

  2024cites this paper
• Who Is responsible for the Opioid Crisis? A Discourse Analysis of Responsibility Claims in Medicine

  2024cites this paper
• Opioid-related clinical outcomes and associated healthcare costs following abuse/misuse of oxycodone formulations: A HEOR analysis from real-world data.

  2024cites this paper
• Closing the Opioid Use Disorder Treatment Gap: Expanding Nurse Practitioners' Prescriptive Authority

  2024cites this paper
• Extended-release and long-acting opioids for chronic pain management.

  2023cites this paper
• Differences in severity of poison centers exposures involving XTAMPZA® ER versus other opioid analgesics.

  2023cites this paper
• The Hazards of Unwinding the Prescription Opioid Epidemic: Implications for Child Maltreatment

  2022cites this paper
• Shifts in substance use patterns among a cohort of people who use opioids after delisting of OxyContin in BC, Canada: An interrupted time series study.

  2022cites this paper
• Choices and Implications when Measuring the Local Supply of Prescription Opioids

  2022cites this paper
• Opioid Exposures Reported to U.S. Poison Centers

  2021cites this paper
• Labor Market Effects of the Oxycodone-Heroin Epidemic

  2021cites this paper
• Retail Pharmacies and Drug Diversion during the Opioid Epidemic

  2020cites this paper
• Pharmacokinetic and pharmacodynamic considerations in developing a response to the opioid epidemic

  2020cites this paper
• The opioid mortality epidemic in North America: do we understand the supply side dynamics of this unprecedented crisis?

  2020cites this paper
• Quality Measures to Reduce Opioid Use After Common Soft Tissue Hand and Wrist Procedures.

  2020cites this paper
• Postmarketing Analysis of Misuse, Abuse, and Diversion of Xtampza ER

  2020cites this paper
• The opioid crisis: Origins, trends, policies, and the roles of pharmacists

  2019cites this paper
• Prevention of Opioid Abuse and Treatment of Opioid Addiction: Current Status and Future Possibilities.

  2019cites this paper
• Real-world misuse, abuse, and dependence of abuse-deterrent versus non-abuse-deterrent extended-release morphine in Medicaid non-cancer patients

  2019cites this paper
• How the Reformulation of OxyContin Ignited the Heroin Epidemic

  2019cites this paper
• Prevention of Opioid Abuse and Treatment of Opioid Addiction : Current Status and Future Possibilities

  2019cites this paper
• Modeling the potential impact of abuse-deterrent opioids on medical resource utilization

  2019cites this paper
• Identifying and classifying opioid‐related overdoses: A validation study

  2019cites this paper
• Important statistical considerations in the evaluation of post‐market studies to assess whether opioids with abuse‐deterrent properties result in reduced abuse in the community

  2018cites this paper
• Post‐marketing studies of pharmaceutical opioid abuse‐deterrent formulations: a framework for research design and reporting

  2018cites this paper
• Abuse-deterrent opioids: an update on current approaches and considerations

  2018cites this paper
• Person-level changes in oxycodone use after the introduction of a tamper-resistant formulation in Australia

  2018cites this paper
• Safety and performance of current abuse-deterrent formulations

  2018cites this paper
• Oral and non-oral routes of administration among prescription opioid users: Pathways, decision-making and directionality.

  2018cites this paper
• DARK Classics in Chemical Neuroscience: Morphine.

  2018cites this paper
• The effect of a potentially tamper-resistant oxycodone formulation on opioid use and harm: main findings of the National Opioid Medications Abuse Deterrence (NOMAD) study.

  2018cites this paper
• Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use

  2017cites this paper
• The Evolution of Abuse-Deterrent Extended-Release Opioid Formulations: Is there a Place in the Armamentarium for More Products?

  2017cites this paper
• Patient-reported pathways to opioid use disorders and pain-related barriers to treatment engagement.

  2017cites this paper
• Abuse-deterrent Opioid Formulations

  2017cites this paper
• New and developing anesthesia drugs

  2017cites this paper
• Changes in drug use patterns reported on the web after the introduction of ADF OxyContin: findings from the Researched Abuse, Diversion, and Addiction‐Related Surveillance (RADARS) System Web Monitoring Program

  2017cites this paper
• Relative preferences in the abuse of immediate‐release versus extended‐release opioids in a sample of treatment‐seeking opioid abusers

  2017cites this paper
• Trends in the Nonmedical Use of OxyContin, United States, 2006 to 2013

  2017cites this paper
• Chronic Pain and the Opioid Conundrum.

  2016cites this paper
• A tale of 2 ADFs: differences in the effectiveness of abuse-deterrent formulations of oxymorphone and oxycodone extended-release drugs

  2016cites this paper
• Supply-Side Drug Policy in the Presence of Substitutes: Evidence from the Introduction of Abuse-Deterrent Opioids.

  2016cites this paper
• Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone.

  2016cites this paper
• Emerging factors in the progression of cancer-related pain.

  2016cites this paper
• Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations

  2016cites this paper
• The effect of an abuse‐deterrent opioid formulation (OxyContin) on opioid abuse‐related outcomes in the postmarketing setting

  2016cites this paper
• Protocol: changes in rates of opioid overdose and poisoning events in an integrated health system following the introduction of a formulation of OxyContin® with abuse-deterrent properties

  2016cites this paper
• Opioid abuse-deterrent strategies: role of clinicians in acute pain management

  2016cites this paper
• Public Health Effects of Medical Marijuana Legalization in Colorado.

  2016cites this paper
• Analysis of the Abuse and Diversion of the Buprenorphine Transdermal Delivery System.

  2016cites this paper
• A Qualitative Analysis of Family Involvement in Prescribed Opioid Medication Monitoring among Individuals who Have Experienced Opioid Overdoses

  2016cites this paper
• Prescription opioid abuse: pharmacists’ perspective and response

  2016cites this paper
• The War on Drugs: Estimating the Effect of Prescription Drug Supply-Side Interventions

  2016cites this paper
• Evaluation of Abuse-Deterrent or Tamper-Resistant Opioid Formulations on Overall Health Care Expenditures in a State Medicaid Program

  2016cites this paper
• Hydrocodone Bitartrate ER (Hysingla® ER): A Review in Chronic Pain

  2016cites this paper
• Gaining Policy Insight with a System Dynamics Model of Pain Medicine Prescribing, Diversion and Abuse

  2016cites this paper
• Prescription Opioid Policy and Illicit Drug Use

  2016influential citation
• Orofacial Pain Team workshop report on the Global Year Against Orofacial Pain

  2016cites this paper
• Abuse Potential Study of ALO-02 (Extended-Release Oxycodone Surrounding Sequestered Naltrexone) Compared with Immediate-Release Oxycodone Administered Orally to Nondependent Recreational Opioid Users

  2016cites this paper
• Decreased diversion by doctor-shopping for a reformulated extended release oxycodone product (OxyContin).

  2016cites this paper
• Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain.

  2016cites this paper
• Clinical Evaluation of Abuse Potential for New Pharmaceuticals: The Assessment of Abuse Potential during Drug Development

  2015cites this paper
• Abuse-deterrent formulations: Part 2: commercial products and proprietary technologies

  2015cites this paper
• Abuse-deterrent formulations: transitioning the pharmaceutical market to improve public health and safety

  2015cites this paper
• The introduction of a potentially abuse deterrent oxycodone formulation: Early findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) study.

  2015cites this paper
• Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.

  2015cites this paper
• Canadian Orofacial Pain Team workshop report on the Global Year Against Orofacial Pain

  2015cites this paper
• Dynamic model of nonmedical opioid use trajectories and potential policy interventions

  2015cites this paper
• Anticipated and unanticipated consequences of abuse deterrent formulations of opioid analgesics

  2015cites this paper
• Impact of abuse‐deterrent OxyContin on prescription opioid utilization

  2015cites this paper
• Abuse-deterrent opioid formulations.

  2015cites this paper
• Methods and predictors of tampering with a tamper-resistant controlled-release oxycodone formulation.

  2015cites this paper
• Trends in opioid analgesic abuse and mortality in the United States.

  2015cites this paper
• Abuse-Deterrent Opioid Formulations.

  2015cites this paper
• Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol.

  2015cites this paper
• The health insurance industry: perpetuating the opioid crisis through policies of cost-containment and profitability

  2015cites this paper
• Prescription Opioid Misuse: Effective Methods for Reducing the Epidemic

  2015cites this paper
• Opioids for low back pain

  2015cites this paper
• A typology of people who tamper with pharmaceutical opioids: responses to introduction of a tamper‐resistant formulation of controlled‐release oxycodone

  2015cites this paper
• Hydrocodone extended-release: pharmacodynamics, pharmacokinetics and behavioral pharmacology of a controversy.

  2015cites this paper
• The Pain Reliever and Heroin Epidemic in the United States: Shifting Winds in the Perfect Storm

  2015cites this paper
• Intranasal administration of crushed ALO‐02 (extended‐release oxycodone with sequestered naltrexone): A randomized, controlled abuse‐potential study in nondependent recreational opioid users

  2015cites this paper
• Abuse-Deterrent Formulations of Prescription Opioids.

  2015cites this paper
• Key Data Gaps Regarding the Public Health Issues Associated with Opioid Analgesics

  2015cites this paper
• The Pain Reliever and Heroin Epidemic in the United States: Shifting Winds in the Perfect Storm.

  2015cites this paper
• Rates of opioid dispensing and overdose after introduction of abuse-deterrent extended-release oxycodone and withdrawal of propoxyphene.

  2015cites this paper
• The characteristics of a cohort who tamper with prescribed and diverted opioid medications.

  2015cites this paper
• Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation†

  2014cites this paper
• Monitoring of Internet Forums to Evaluate Reactions to the Introduction of Reformulated OxyContin to Deter Abuse

  2014cites this paper
• Abuse and diversion of buprenorphine sublingual tablets and film.

  2014cites this paper
• The US FDA Draft Guidance for Developing Abuse-Deterrent Opioid Analgesics: 2014 and Beyond

  2014cites this paper
• Chronic pain, addiction, and Zohydro.

  2014cites this paper
• Oxycodone/Naloxone: Role in Chronic Pain Management, Opioid-Induced Constipation, and Abuse Deterrence

  2014cites this paper
• Painful decision-making at FDA

  2014cites this paper
• The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers.

  2014cites this paper
• Opioid formulations with sequestered naltrexone: a perspective review

  2014cites this paper
• Measures to quantify the abuse of prescription opioids: a review of data sources and metrics

  2014cites this paper
• Opioid management of pain: the impact of the prescription opioid abuse epidemic

  2014cites this paper